Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy
Pharmaceutics · 16.02.2024 · 16 (2) · 277
DOI: 10.3390/pharmaceutics16020277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.02.2024. Verfasst von Giuseppe Francesco Racaniello und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Programma Operativo Nazionale (PON).
Abstract (Originalsprache)
Cataract surgery interventions are constantly increasing, particularly among adult and elderly patients. This type of surgery can lead to inflammatory states of the ocular anterior segment (AS), usually healed via postoperative treatment with dexamethasone (DEX)-containing eye drops. The application of eye drops is challenging due to the high number of daily administrations. In this study, mucoadhesive nanoparticles (NPs) were formulated to improve the residence time of DEX on the corneal mucosa, enhancing the drug’s solubility and bioavailability. The NPs were generated using an ionotropic gelation technique, exploiting the interaction between the cationic group of chitosan (CS) and the anionic group of sulfobutylether-β-cyclodextrin (SBE-β-CD). The formation of the inclusion complex and its stoichiometry were studied through phase solubility studies, Job’s plot method, and Bi-directional transport studies on MDCKII-MDR1. The obtained NPs showed good chemical and physical characteristics suitable for drug loading and subsequent testing on animal mucosa. The DEX-loaded CS/SBE-β-CD NPs exhibited a prolonged residence time on animal mucosa and demonstrated enhanced drug permeability through the corneal membrane, showing a sustained release profile. The developed NPs posed no irritation or toxicity concerns upon local administration, making them an optimal and innovative drug delivery system for inflammatory AS diseases treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
- Faculty of Pharmaceutical Sciences, University of Iceland, 107 Reykjavik, Iceland.
ORCID-Profile: Gennaro Balenzano, Rosa Maria Iacobazzi, Antonio Lopalco, Hakon Hrafn Sigurdsson, Nunzio Denora
Förderung
- Programma Operativo Nazionale (PON)
Zitieren
APA
Racaniello, G. F., Balenzano, G., Arduino, I., Iacobazzi, R. M., Lopalco, A., Lopedota, A. A., Sigurdsson, H. H., & Denora, N. (2024). Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy. Pharmaceutics, 16(2), 277. https://doi.org/10.3390/pharmaceutics16020277
Vancouver
Racaniello GF, Balenzano G, Arduino I, Iacobazzi RM, Lopalco A, Lopedota AA, et al. Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy. Pharmaceutics. 2024;16(2):277. doi:10.3390/pharmaceutics16020277
BibTeX
@article{Racaniello2024,
author = {Racaniello, Giuseppe Francesco and Balenzano, Gennaro and Arduino, Ilaria and Iacobazzi, Rosa Maria and Lopalco, Antonio and Lopedota, Angela Assunta and Sigurdsson, Hakon Hrafn and Denora, Nunzio},
title = {Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {2},
pages = {277},
doi = {10.3390/pharmaceutics16020277}
}
EUVIMED